Anxiety Disorders: Diagnosis, Treatment Options & Monitoring

Anxiety disorders encompass discrete DSM-5 diagnoses in which fear, anxiety, or related avoidance is excessive for context, persistent, and functionally impairing. Neurobiologically they reflect dysregulated threat detection across prefrontal–limbic–autonomic loops; clinically they present as worry storms, situational avoidance, panic surges, obsessional doubting, or trauma-linked hypervigilance depending on syndrome.

Patients rarely carry a single “pure” form—mixed presentations with anxiety symptoms, depressive symptoms, somatic preoccupation, and substance coping are the norm in acute medical settings. Management therefore pairs disorder-specific psychoeducation with staged interventions that balance benefit, adverse-effect burden, and patient preference.

Health systems increasingly expect nurses and allied staff to screen sensitively, monitor early pharmacotherapy, coordinate psychological care, and recognise when anxiety complaints signal occult medical disease or life-threatening psychiatric emergencies.

Mapping presentations to DSM-5 categories guides therapy selection—exposure parameters differ between agoraphobia, social performance fears, and generalized worry.

↔On a small screen, swipe or scroll sideways to see the full table.

OCD, PTSD, adjustment disorders, and mood episodes sit adjacent in differential and often require separate guideline pathways even when anxiety is prominent.

Patients may present through mental health clinics, primary care, obstetric liaison, cardiology fast-track, or distressed admission assessments. Language, literacy, and cultural idioms shape how “worry” is expressed—always validate somatic complaints while investigating serious differentials.

Typical clusters

• Cognitive: catastrophizing, attention narrowing, rumination, fear of losing control.
• Autonomic: tachycardia, sweating, tremor, dyspnoea, gastrointestinal upset.
• Behavioural: avoidance, reassurance seeking, safety behaviours, work or school impairment.

Variants that need extra curiosity

• Children/teens with abdominal pain, school refusal, or irritability rather than classic worry narrative.
• Older adults who minimise psychological labels yet report dizziness, falls, or unstable vitals during panic.
• Postpartum parents with intrusive fears of harm—distinguish perinatal OCD from psychosis urgently.

Heritability is moderate polygenic; environmental load from childhood adversity, bullying, chronic pain, or occupational moral injury raises onset risk. Medical factors—pulmonary disease, hyperthyroidism, pheochromocytoma, seizure disorders—can mimic primary anxiety synchronously.

Modifiable contributors

• Excess caffeine, nicotine cycling, and recreational stimulants lower panic threshold.
• Erratic sleep and shift work erode prefrontal regulation of amygdala drive.
• Alcohol “self-medication” predisposes to rebound anxiety and withdrawal emergencies.

Protective levers

• Stable routines, graded activity despite fear, peer-supported exposure homework.
• Employer/education accommodations that enable gradual re-entry after prolonged avoidance.

Diagnosis is clinical, supported by structured interviews and validated scales; laboratories and imaging exclude mimics rather than “confirm” psychiatric disease.

Clinical assessment

Map onset, course, triggers, avoidance, trauma history, developmental stage, previous treatments, and collateral when permitted. Screen explicitly for major depression, manic switches, eating disorder, and neurodevelopmental patterns that reshape medication choices.

Laboratory investigations

• Directed metabolic screening—e.g. electrolyte panel, glucose (per pathway), thyroid tests when hypermetabolic signs exist.
• Pregnancy status before radiology or teratogenic drug discussion.

Imaging

Use chest X-ray, thyroid ultrasound, or CT only when examination and risk scores warrant—avoid shotgun tests that reinforce illness anxiety without changing management.

Diagnostic criteria / tools

DSM-5 duration thresholds (often ≥6 months for generalized patterns) plus impairment criteria distinguish disorder from normative stress. GAD-7, PHQ-9 (depression overlap), PDSS, LSAS, or Y-BOCS scores augment but do not replace clinician judgment.

1. Triage safety: address suicidality, medical instability, substance withdrawal, and safeguarding before deep history.
2. Match syndrome: differentiate GAD, panic, social anxiety, phobia, OCD/trauma—affects therapy homework.
3. Stage intervention: psychoeducation + CBT wait-list → consider SSRI/SNRI with monitoring checklist → reserve benzodiazepines for crisis per policy.
4. Reassess response: at 4–6 weeks after therapeutic dose—earlier if severe adverse effects or worsening mood.
5. Escalate: complex PTSD, treatment-refractory OCD, eating disorder, bipolar features, or inpatient risk to specialist MDT.

↔On a small screen, swipe or scroll sideways to see the full table.

First-line management

• Individual or group CBT emphasizing psychoeducation, cognitive restructuring, and graded exposure homework.
• SSRIs such as escitalopram or sertraline; SNRIs such as venlafaxine when comorbid pain or prior SSRI failure under specialist guidance.
• Buspirone as augment or partial response option in some GAD cohorts per prescriber.

Second-line / situational pharmacology

• Situational performance anxiety may use propranolol when asthma/bradycardia contraindications absent—cardiology-aware.
• Short benzodiazepine courses for crisis only—avoid opioid co-prescribing and document taper expectations.

Special populations

• Pregnancy/lactation: involve perinatal psychiatry; prioritize therapy and lowest-risk agents per shared decision-making.
• Youth: start low/go slow; monitor activation and suicidal ideation especially in first weeks.
• Older adults: lean toward therapy, minimise anticholinergic load, guard falls with sedatives.

• Establish baseline vital signs, weight, suicidality, and scale scores before starting/restarting antidepressants.
• Education: explain latency, early nausea/activation, sexual side effects, bleeding risk with NSAIDs/anticoagulants, hyponatraemia symptoms.
• Follow-up at 1–2 weeks after dose change, then 4–12 weekly if stable—sooner for pregnancy, adolescents, or prior self-harm.
• Treatment failure = no meaningful improvement after 6 weeks at therapeutic SSRI dose—psychiatry referral for augmentation strategies (e.g., buspirone, second-generation antipsychotic micro-augment in refractory GAD per specialist only).
• MDT roles: psychologists deliver exposure protocols, pharmacists reconcile sedatives, occupational therapy supports graded community re-entry.

• Comorbid major depression, alcohol use, or chronic pain syndromes prolong recovery.
• Medication adverse effects leading to abrupt dropout— anticipate and pre-empt with prophylaxis or slower titration.
• Chronic avoidance producing job loss, relationship rupture, or deconditioning.
• Iatrogenic harms from long sedative courses—dependence, cognitive slowing, falls.

USPSTF recommends anxiety screening in selected adult and pediatric cohorts when services can deliver follow-up; nurses can embed PHQ/GAD tools into routine visits without pathologizing normal stress responses.

• School and workplace programmes teaching coping skills show modest anxiety reduction in community samples.
• Early trauma-informed counselling after adverse events may reduce chronic PTSD emergence where available.

With structured CBT and/or appropriate pharmacotherapy most patients achieve clinically meaningful improvement within months, though residual worry or situational triggers may persist. Relapse after medication discontinuation remains possible—taper slowly and maintain booster therapy sessions.

Nursing input often determines whether patients feel safe enough to attempt exposures or adhere to antidepressant titrations.

Communication and environment

• Lower sensory load on hyper-aroused patients; offer predictable timelines; use trauma-informed language.
• Normalize bodily anxiety sensations while reinforcing that cardiopulmonary checks protect them—not dismiss them.

Medication safety

• Teach PRN lorazepam boundaries: frequency caps, no alcohol, no driving if sedated.
• Document early SSRI adverse events and syncope episodes for prescriber review.

Documentation & escalation

• Record verbatim suicidal statements, plans, and protective factors; follow local self-harm policy immediately.
• Flag domestic violence or safeguarding concerns concurrent with anxiety presentations.

• Active suicidal plan, command hallucinations harming self/others, or peripartum psychosis features.
• Severe dehydration, intractable vomiting, or suspected serotonin toxicity after poly-drug use.
• Panic symptoms plus focal neurological signs, syncope with injury, or ST-segment changes—treat as medical emergency.

Activate emergency medical services or hospital-acute pathways per local protocol while maintaining continuous observation until senior review.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of generalised, panic and social anxiety, CBT-first stewardship, SSRI / SNRI pharmacotherapy and the suicide / serotonin-syndrome red flags.